Skip to main content
Top
Published in: Journal of Endocrinological Investigation 3/2017

01-03-2017 | Review

How the reference values for serum parathyroid hormone concentration are (or should be) established?

Authors: J.-C. Souberbielle, F. Brazier, M.-L. Piketty, C. Cormier, S. Minisola, E. Cavalier

Published in: Journal of Endocrinological Investigation | Issue 3/2017

Login to get access

Abstract

Well-validated reference values are necessary for a correct interpretation of a serum PTH concentration. Establishing PTH reference values needs recruiting a large reference population. Exclusion criteria for this population can be defined as any situation possibly inducing an increase or a decrease in PTH concentration. As recommended in the recent guidelines on the diagnosis and management of asymptomatic primary hyperparathyroidism, PTH reference values should be established in vitamin D-replete subjects with a normal renal function with possible stratification according to various factors such as age, gender, menopausal status, body mass index, and race. A consensus about analytical/pre-analytical aspects of PTH measurement is also needed with special emphasis on the nature of the sample (plasma or serum), the time and the fasting/non-fasting status of the blood sample. Our opinion is that blood sample for PTH measurement should be obtained in the morning after an overnight fast. Furthermore, despite longer stability of the PTH molecule in EDTA plasma, we prefer serum as it allows to measure calcium, a prerequisite for a correct interpretation of a PTH concentration, on the same sample. Once a consensus is reached, we believe an important international multicentre work should be performed to recruit a very extensive reference population of apparently healthy vitamin D-replete subjects with a normal renal function in order to establish the PTH normative data. Due to the huge inter-method variability in PTH measurement, a sufficient quantity of blood sample should be obtained to allow measurement with as many PTH kits as possible.
Literature
1.
go back to reference Souberbielle JC, Cormier C, Cavalier E (2015) How to manage an isolated elevated PTH? Ann Endocrinol 76:134–141CrossRef Souberbielle JC, Cormier C, Cavalier E (2015) How to manage an isolated elevated PTH? Ann Endocrinol 76:134–141CrossRef
2.
go back to reference Eastell R, Arnold A, Brandi ML, Brown EM, D’Amour P, Hanley D et al (2009) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 94:340–350CrossRefPubMed Eastell R, Arnold A, Brandi ML, Brown EM, D’Amour P, Hanley D et al (2009) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 94:340–350CrossRefPubMed
3.
go back to reference Bilezikian J, Brandi ML, Eastell R, Silverberg S, Udelsman R, Marcocci C et al (2014) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the fourth international workshop. J Clin Endocrinol Metab 99:3561–3569CrossRefPubMed Bilezikian J, Brandi ML, Eastell R, Silverberg S, Udelsman R, Marcocci C et al (2014) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the fourth international workshop. J Clin Endocrinol Metab 99:3561–3569CrossRefPubMed
4.
go back to reference Nussbaum SR, Zahradnik RJ, Lavigne JR, Brennan GL, Nozawa-Ung K, Kim LY et al (1987) Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 33:1364–1367PubMed Nussbaum SR, Zahradnik RJ, Lavigne JR, Brennan GL, Nozawa-Ung K, Kim LY et al (1987) Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 33:1364–1367PubMed
5.
go back to reference Lepage R, Roy L, Brossard JH, Rousseau L, Dorais C, Lazure C et al (1998) A non (1–84) circulating parathyroid hormone fragment interferes significantly with intact PTH commercial assay in uremic samples. Clin Chem 44:4287–4290 Lepage R, Roy L, Brossard JH, Rousseau L, Dorais C, Lazure C et al (1998) A non (1–84) circulating parathyroid hormone fragment interferes significantly with intact PTH commercial assay in uremic samples. Clin Chem 44:4287–4290
6.
go back to reference John M, Goodman W, Gao P, Cantor T, Salusky I, Juppner H (1999) A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab 84:4287–4290CrossRefPubMed John M, Goodman W, Gao P, Cantor T, Salusky I, Juppner H (1999) A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab 84:4287–4290CrossRefPubMed
7.
go back to reference Cavalier E, Daly AF, Betea D, Pruteanu-Apetrii P, Delanaye P, Stubbs P et al (2010) The ratio of parathyroid hormone as measured by third- and second-generation assays as a marker for parathyroid carcinoma. J Clin Endocrinol Metab 95:3745–3749CrossRefPubMed Cavalier E, Daly AF, Betea D, Pruteanu-Apetrii P, Delanaye P, Stubbs P et al (2010) The ratio of parathyroid hormone as measured by third- and second-generation assays as a marker for parathyroid carcinoma. J Clin Endocrinol Metab 95:3745–3749CrossRefPubMed
8.
go back to reference Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E et al (2006) Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 70:345–350CrossRefPubMed Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E et al (2006) Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 70:345–350CrossRefPubMed
9.
go back to reference Joly D, Drueke T, Alberti C, Houillier P, Lawson-Body E, Martin K et al (2008) Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study. Am J Kidney Dis 51:987–995CrossRefPubMed Joly D, Drueke T, Alberti C, Houillier P, Lawson-Body E, Martin K et al (2008) Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study. Am J Kidney Dis 51:987–995CrossRefPubMed
10.
go back to reference Touvier M, Deschasaux M, Montourcy M, Sutton A, Charnuax N, Kess-Guyot E et al (2014) Interpretation of plasma PTH concentrations according to 25OHD status, gender, age, weight status, and calcium intake: importance of the reference values. J Clin Endocrinol Metab 99:1196–1203CrossRefPubMed Touvier M, Deschasaux M, Montourcy M, Sutton A, Charnuax N, Kess-Guyot E et al (2014) Interpretation of plasma PTH concentrations according to 25OHD status, gender, age, weight status, and calcium intake: importance of the reference values. J Clin Endocrinol Metab 99:1196–1203CrossRefPubMed
11.
go back to reference Björkman M, Sorva A, Tilvis R (2009) Responses of parathyroid hormone to vitamin D supplementation: a systematic review of clinical trials. Arch Gerontol Geriatr 48:160–166CrossRefPubMed Björkman M, Sorva A, Tilvis R (2009) Responses of parathyroid hormone to vitamin D supplementation: a systematic review of clinical trials. Arch Gerontol Geriatr 48:160–166CrossRefPubMed
12.
go back to reference Blind E, Schmidt-Gayk H, Scharla S, Flentje D, Fischer S, Göhring U et al (1988) Two-site assay of intact parathyroid hormone in the investigation of primary hyperparathyroidism and other disorders of calcium metabolism compared with a mid-region assay. J Clin Endocrinol Metab 67:353–360CrossRefPubMed Blind E, Schmidt-Gayk H, Scharla S, Flentje D, Fischer S, Göhring U et al (1988) Two-site assay of intact parathyroid hormone in the investigation of primary hyperparathyroidism and other disorders of calcium metabolism compared with a mid-region assay. J Clin Endocrinol Metab 67:353–360CrossRefPubMed
13.
go back to reference Endres D, Villanueva R, Sharp C Jr, Singer F (1991) Immunochemiluminometric and immunoradiometric determinations of intact and total immunoreactive parathyrin: performance in the differential diagnosis of hypercalcemia and hypoparathyroidism. Clin Chem 37:162–168PubMed Endres D, Villanueva R, Sharp C Jr, Singer F (1991) Immunochemiluminometric and immunoradiometric determinations of intact and total immunoreactive parathyrin: performance in the differential diagnosis of hypercalcemia and hypoparathyroidism. Clin Chem 37:162–168PubMed
14.
go back to reference Ratcliffe W, Heath D, Ryan M, Jones S (1989) Performance and diagnostic application of a two-site immunometric assay for parathyrin in serum. Clin Chem 35:1957–1961PubMed Ratcliffe W, Heath D, Ryan M, Jones S (1989) Performance and diagnostic application of a two-site immunometric assay for parathyrin in serum. Clin Chem 35:1957–1961PubMed
15.
go back to reference Gao P, Scheibel S, D’Amour P, John M, Rao S, Schmidt-Gayk H et al (2001) Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1–84: implication for improvement of accurate assessment of parathyroid function. J Bone Miner Res 16:605–614CrossRefPubMed Gao P, Scheibel S, D’Amour P, John M, Rao S, Schmidt-Gayk H et al (2001) Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1–84: implication for improvement of accurate assessment of parathyroid function. J Bone Miner Res 16:605–614CrossRefPubMed
16.
go back to reference Souberbielle JC, Cormier C, Kindermans C, Gao P, Cantor T, Forette F et al (2001) Vitamin D status and redefining serum parathyroid hormone reference range. J Clin Endocrinol Metab 86:3086–3090PubMed Souberbielle JC, Cormier C, Kindermans C, Gao P, Cantor T, Forette F et al (2001) Vitamin D status and redefining serum parathyroid hormone reference range. J Clin Endocrinol Metab 86:3086–3090PubMed
17.
go back to reference Glendenning P, Vasikaran S (2002) Comment on: Vitamin D status and redefining serum PTH reference range in the elderly. J Clin Endocrinol Metab 97:946–947CrossRef Glendenning P, Vasikaran S (2002) Comment on: Vitamin D status and redefining serum PTH reference range in the elderly. J Clin Endocrinol Metab 97:946–947CrossRef
18.
go back to reference Souberbielle JC, Fayol V, Sault C, Lawson-Body E, Kahan A, Cormier A (2005) Assay-specific decision limits for two new automated parathyroid hormone and 25-hydroxyvitamin D assays. Clin Chem 51:395–400CrossRefPubMed Souberbielle JC, Fayol V, Sault C, Lawson-Body E, Kahan A, Cormier A (2005) Assay-specific decision limits for two new automated parathyroid hormone and 25-hydroxyvitamin D assays. Clin Chem 51:395–400CrossRefPubMed
20.
go back to reference La’ulu S, Roberts W (2010) Performance characteristics of six intact parathyroid hormone assays. Am J Clin Pathol 134:930–938CrossRefPubMed La’ulu S, Roberts W (2010) Performance characteristics of six intact parathyroid hormone assays. Am J Clin Pathol 134:930–938CrossRefPubMed
21.
go back to reference Rejnmark L, Vestergaard P, Heickendorff L, Mosekilde L (2011) Determinants of plasma PTH and their implication for defining a reference interval. Clin Endocrinol 74:37–43CrossRef Rejnmark L, Vestergaard P, Heickendorff L, Mosekilde L (2011) Determinants of plasma PTH and their implication for defining a reference interval. Clin Endocrinol 74:37–43CrossRef
22.
go back to reference Fillée C, Keller T, Mourad M, Brikman T, Ketelslegers JM (2012) Impact of vitamin D-related serum PTH reference values on the diagnosis of mild primary hyperparathyroidism, using bivariate calcium/PTH reference regions. Clin Endocrinol 76:785–789CrossRef Fillée C, Keller T, Mourad M, Brikman T, Ketelslegers JM (2012) Impact of vitamin D-related serum PTH reference values on the diagnosis of mild primary hyperparathyroidism, using bivariate calcium/PTH reference regions. Clin Endocrinol 76:785–789CrossRef
23.
go back to reference Cavalier E, Delanaye P, Vranken L, Bekaert AC, Carlisi A, Chapelle JP et al (2012) Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: importance of the reference (normal) values. Nephrol Dial Transpl 27:1950–1956CrossRef Cavalier E, Delanaye P, Vranken L, Bekaert AC, Carlisi A, Chapelle JP et al (2012) Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: importance of the reference (normal) values. Nephrol Dial Transpl 27:1950–1956CrossRef
24.
go back to reference Deckers M, de Jongh R, Lips P, Penninx B, Milaschi Y, Smit J et al (2013) Prevalence of vitamin D deficiency and consequences for PTH reference values. Clin Chim Acta 426:41–45CrossRefPubMed Deckers M, de Jongh R, Lips P, Penninx B, Milaschi Y, Smit J et al (2013) Prevalence of vitamin D deficiency and consequences for PTH reference values. Clin Chim Acta 426:41–45CrossRefPubMed
25.
go back to reference Djennane M, Lebbah S, Roux C, Djoudi H, Cavalier E, Souberbielle JC (2014) Vitamin D status of schoolchildren in Northern Algeria, seasonal variations and determinants of vitamin D deficiency. Osteoporos Int 25:1493–1502CrossRefPubMed Djennane M, Lebbah S, Roux C, Djoudi H, Cavalier E, Souberbielle JC (2014) Vitamin D status of schoolchildren in Northern Algeria, seasonal variations and determinants of vitamin D deficiency. Osteoporos Int 25:1493–1502CrossRefPubMed
26.
go back to reference Li M, Lv F, Zhang Z, Deng W, Li Y, Deng Z et al (2016) Establishment of a normal reference value of parathyroid hormone in a large healthy Chinese population and evaluation of its relation to bone turnover and bone mineral density. Osteoporos Int 27:1907–1916CrossRefPubMed Li M, Lv F, Zhang Z, Deng W, Li Y, Deng Z et al (2016) Establishment of a normal reference value of parathyroid hormone in a large healthy Chinese population and evaluation of its relation to bone turnover and bone mineral density. Osteoporos Int 27:1907–1916CrossRefPubMed
27.
go back to reference Souberbielle JC, Massart C, Brailly-Tabard S, Cormier C, Cavalier E, Delanaye P et al (2016) Serum PTH reference values established by an automated third-generation assay in vitamin D-replete subjects with normal renal function: consequences of diagnosing primary hyperparathyroidism and the classification of dialysis patients. Eu J Endocrinol 174:315–323CrossRef Souberbielle JC, Massart C, Brailly-Tabard S, Cormier C, Cavalier E, Delanaye P et al (2016) Serum PTH reference values established by an automated third-generation assay in vitamin D-replete subjects with normal renal function: consequences of diagnosing primary hyperparathyroidism and the classification of dialysis patients. Eu J Endocrinol 174:315–323CrossRef
28.
go back to reference Ross C, Manson JE, Abrams S, Aloia J, Brannon P, Clinton S et al (2011) The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 96:53–58CrossRefPubMed Ross C, Manson JE, Abrams S, Aloia J, Brannon P, Clinton S et al (2011) The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 96:53–58CrossRefPubMed
29.
go back to reference Holick M, Binkley N, Bischoff-Ferrari H, Gordon C, Hanley D, Heaney R et al (2011) Evaluation, treatment and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1911–1930CrossRefPubMed Holick M, Binkley N, Bischoff-Ferrari H, Gordon C, Hanley D, Heaney R et al (2011) Evaluation, treatment and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1911–1930CrossRefPubMed
30.
go back to reference KDIGO C-M (2009) Work Group KDIGO Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone disorder (CKD-MBD). Kidney Int 76(Suppl 113):S1–130 KDIGO C-M (2009) Work Group KDIGO Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone disorder (CKD-MBD). Kidney Int 76(Suppl 113):S1–130
31.
go back to reference Bell NH, Greene A, Epstein S, Oexmann MJ, Shaw S, Shary JR (1985) Evidence for alteration of the vitamin D-endocrine system in blacks. J Clin Invest 76:470–473CrossRefPubMedPubMedCentral Bell NH, Greene A, Epstein S, Oexmann MJ, Shaw S, Shary JR (1985) Evidence for alteration of the vitamin D-endocrine system in blacks. J Clin Invest 76:470–473CrossRefPubMedPubMedCentral
32.
go back to reference Quesada JM, Coopmans W, Ruiz B, Aljam P, Jans I, Bouillon R (1992) Influence of vitamin D on parathyroid hormone in the elderly. J Clin Endocrinol Metab 75:494–501PubMed Quesada JM, Coopmans W, Ruiz B, Aljam P, Jans I, Bouillon R (1992) Influence of vitamin D on parathyroid hormone in the elderly. J Clin Endocrinol Metab 75:494–501PubMed
33.
go back to reference Valcour A, Blocki F, Hawkins DM, Rao SD (2012) Effects of age and serum 25OHD-vitamin D levels on serum parathyroid hormone levels. J Clin Endocrinol Metab 97:3989–3995CrossRefPubMed Valcour A, Blocki F, Hawkins DM, Rao SD (2012) Effects of age and serum 25OHD-vitamin D levels on serum parathyroid hormone levels. J Clin Endocrinol Metab 97:3989–3995CrossRefPubMed
34.
go back to reference Bailey D, Colantino D, Kuriakopoulou L, Cohen A, Chan MK, Armbruster D et al (2013) Marked biological variance in endocrine and biochemical markers in childhood: establishment of pediatric reference intervals using healthy community children from CALIPER cohort. Clin Chem 59:1393–1405CrossRefPubMed Bailey D, Colantino D, Kuriakopoulou L, Cohen A, Chan MK, Armbruster D et al (2013) Marked biological variance in endocrine and biochemical markers in childhood: establishment of pediatric reference intervals using healthy community children from CALIPER cohort. Clin Chem 59:1393–1405CrossRefPubMed
35.
go back to reference Soldin O, Dahlin J, Gresham E, King J, Soldin S (2008) Immulite 2000 age and sex-specific reference intervals for alpha fetoprotein, homocysteine, insulin, insulin-like growth factor-1, insulin-like growth factor binding protein-3, C-peptide, immunoglobulin E and intact parathyroid hormone. Clin Biochem 41:937–942CrossRefPubMedPubMedCentral Soldin O, Dahlin J, Gresham E, King J, Soldin S (2008) Immulite 2000 age and sex-specific reference intervals for alpha fetoprotein, homocysteine, insulin, insulin-like growth factor-1, insulin-like growth factor binding protein-3, C-peptide, immunoglobulin E and intact parathyroid hormone. Clin Biochem 41:937–942CrossRefPubMedPubMedCentral
36.
go back to reference Kovacs C, Kronenberg H (1997) Maternal-fetal calcium and bone metabolism during pregnancy, puerperium, and lactation. Endocr Rev 18:832–872PubMed Kovacs C, Kronenberg H (1997) Maternal-fetal calcium and bone metabolism during pregnancy, puerperium, and lactation. Endocr Rev 18:832–872PubMed
37.
go back to reference Frolich A, Rudnicki M, Fischer-Rasmussen W, Olofsson K (1991) Serum concentration of intact parathyroid hormone during late human pregnancy: a longitudinal study. Eur J Obstet Gynecol Reprod Biol 42:85–87CrossRefPubMed Frolich A, Rudnicki M, Fischer-Rasmussen W, Olofsson K (1991) Serum concentration of intact parathyroid hormone during late human pregnancy: a longitudinal study. Eur J Obstet Gynecol Reprod Biol 42:85–87CrossRefPubMed
38.
go back to reference Seely EW, Brown E, DeMaggio D, Weldon D, Graves S (1997) A prospective study of calciotropic hormones in pregnancy and post partum: reciprocal changes in serum intact parathyroid hormone and 1,25-dihydroxyvitamin D. Am J Obstet Gynecol 176:214–217CrossRefPubMed Seely EW, Brown E, DeMaggio D, Weldon D, Graves S (1997) A prospective study of calciotropic hormones in pregnancy and post partum: reciprocal changes in serum intact parathyroid hormone and 1,25-dihydroxyvitamin D. Am J Obstet Gynecol 176:214–217CrossRefPubMed
39.
go back to reference Saggese G, Baroncelli GI, Bertelloni S, Cipolloni C (1991) Intact parathyroid hormone levels during pregnancy, in healthy term neonates and in hypocalcemic preterm infants. Acta Paediatr Scand 80:36–41CrossRefPubMed Saggese G, Baroncelli GI, Bertelloni S, Cipolloni C (1991) Intact parathyroid hormone levels during pregnancy, in healthy term neonates and in hypocalcemic preterm infants. Acta Paediatr Scand 80:36–41CrossRefPubMed
40.
go back to reference Cross N, Hillman L, Allen S, Krause G, Vieira N (1995) Calcium homeostasis and bone metabolism during pregnancy, lactation, and postweaning: a longitudinal study. Am J Clin Nutr 61:514–523PubMed Cross N, Hillman L, Allen S, Krause G, Vieira N (1995) Calcium homeostasis and bone metabolism during pregnancy, lactation, and postweaning: a longitudinal study. Am J Clin Nutr 61:514–523PubMed
41.
go back to reference More C, Bhattoa HP, Bettembuk P, Balogh A (2003) The effect of pregnancy and lactation on hormonal status and biochemical markers of bone turnover. Eur J Obstet Gynecol Reprod Biol 106:209–213CrossRefPubMed More C, Bhattoa HP, Bettembuk P, Balogh A (2003) The effect of pregnancy and lactation on hormonal status and biochemical markers of bone turnover. Eur J Obstet Gynecol Reprod Biol 106:209–213CrossRefPubMed
42.
go back to reference Uemura H, Yasui T, Kiyokawa M, Kuwahara A, Ikawa H, Matsuzaki T et al (2002) Serum osteoprotegerin/osteoclastogenesis-inhibitory factor during pregnancy and lactation and the relationship with calcium-regulating hormones and bone turnover markers. J Endocrinol 174:353–359CrossRefPubMed Uemura H, Yasui T, Kiyokawa M, Kuwahara A, Ikawa H, Matsuzaki T et al (2002) Serum osteoprotegerin/osteoclastogenesis-inhibitory factor during pregnancy and lactation and the relationship with calcium-regulating hormones and bone turnover markers. J Endocrinol 174:353–359CrossRefPubMed
43.
go back to reference Kramer C, Ye C, Hanley A, Connelly P, Sermer M, Zinman B et al (2016) The relationship between parathyroid hormone and 25-hydroxyvitamin D during and after pregnancy. J Clin Endocrinol Metab 101:1729–1736CrossRefPubMed Kramer C, Ye C, Hanley A, Connelly P, Sermer M, Zinman B et al (2016) The relationship between parathyroid hormone and 25-hydroxyvitamin D during and after pregnancy. J Clin Endocrinol Metab 101:1729–1736CrossRefPubMed
44.
go back to reference Fuleihan GEH, Klerman E, Brown E, Choe Y, Brown E, Czeisler C (1997) The parathyroid hormone circadian rhythm is truly endogenous—a general clinical research center study. J Clin Endocrinol Metab 82:281–286 Fuleihan GEH, Klerman E, Brown E, Choe Y, Brown E, Czeisler C (1997) The parathyroid hormone circadian rhythm is truly endogenous—a general clinical research center study. J Clin Endocrinol Metab 82:281–286
45.
go back to reference Rejnmark L, Lauridsen A, Vestergaard P, Heickendorff L, Andreasen F, Mosekilde L (2002) Diurnal rhythm of plasma 1,25-dihydroxyvitamin D and vitamin D-binding protein in postmenopausal women: relationship to plasma parathyroid hormone and calcium and phosphate metabolism. Eur J Endocrinol 146:635–642CrossRefPubMed Rejnmark L, Lauridsen A, Vestergaard P, Heickendorff L, Andreasen F, Mosekilde L (2002) Diurnal rhythm of plasma 1,25-dihydroxyvitamin D and vitamin D-binding protein in postmenopausal women: relationship to plasma parathyroid hormone and calcium and phosphate metabolism. Eur J Endocrinol 146:635–642CrossRefPubMed
46.
go back to reference Smith E, Cai M, McMahon L, Holt S (2012) Biological variability of plasma intact and C-terminal FGF23 measurements. J Clin Endocrinol Metab 97:3501–3504 Smith E, Cai M, McMahon L, Holt S (2012) Biological variability of plasma intact and C-terminal FGF23 measurements. J Clin Endocrinol Metab 97:3501–3504
47.
go back to reference Horn PS, Feng L, Li Y, Pesce AJ (2001) Effect of outliers and nonhealthy individuals on reference interval estimation. Clin Chem 47:2137–2145PubMed Horn PS, Feng L, Li Y, Pesce AJ (2001) Effect of outliers and nonhealthy individuals on reference interval estimation. Clin Chem 47:2137–2145PubMed
48.
go back to reference Souberbielle JC, Lawson-Body E, Hammadi B, Sarfati E, Kahan A, Cormier C (2003) The use in clinical practice of parathyroid hormone normative values established in vitamin D-sufficient subjects. J Clin Endocrinol Metab 88:3501–3504CrossRefPubMed Souberbielle JC, Lawson-Body E, Hammadi B, Sarfati E, Kahan A, Cormier C (2003) The use in clinical practice of parathyroid hormone normative values established in vitamin D-sufficient subjects. J Clin Endocrinol Metab 88:3501–3504CrossRefPubMed
49.
go back to reference Koumakis E, Souberbielle JC, Sarfati E, Meunier M, Maury E, Gallimard E et al (2013) Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab 98:3213–3220CrossRefPubMed Koumakis E, Souberbielle JC, Sarfati E, Meunier M, Maury E, Gallimard E et al (2013) Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab 98:3213–3220CrossRefPubMed
50.
go back to reference van Ballegooijen A, Reinders I, Visser M, Brouwer I (2013) Parathyroid hormone and cardiovascular disease events: a systematic review and meta-analysis of prospective studies. Am Heart J 165:655–664CrossRefPubMed van Ballegooijen A, Reinders I, Visser M, Brouwer I (2013) Parathyroid hormone and cardiovascular disease events: a systematic review and meta-analysis of prospective studies. Am Heart J 165:655–664CrossRefPubMed
51.
go back to reference Yang B, Lu C, Wu Q, Zhang J, Zhao H, Cao Y (2016) Parathyroid hormone, cardiovascular and all-cause mortality: a meta-analysis. Clin Chim Acta 455:154–160CrossRefPubMed Yang B, Lu C, Wu Q, Zhang J, Zhao H, Cao Y (2016) Parathyroid hormone, cardiovascular and all-cause mortality: a meta-analysis. Clin Chim Acta 455:154–160CrossRefPubMed
Metadata
Title
How the reference values for serum parathyroid hormone concentration are (or should be) established?
Authors
J.-C. Souberbielle
F. Brazier
M.-L. Piketty
C. Cormier
S. Minisola
E. Cavalier
Publication date
01-03-2017
Publisher
Springer International Publishing
Published in
Journal of Endocrinological Investigation / Issue 3/2017
Electronic ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-016-0553-2

Other articles of this Issue 3/2017

Journal of Endocrinological Investigation 3/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine